Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms

O Spigset1, K Granberg, S Hägg

  • 1Division of Clinical Pharmacology, Norrland University Hospital, Umeä, Sweden.

European Journal of Clinical Pharmacology
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Connections between cross-tissue and intra-tissue biomarkers of aging biology in older adults.

Epigenetics communications·2023
Same author

Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database.

Psychological medicine·2022
Same author

Body mass index and Mini Nutritional Assessment-Short Form as predictors of in-geriatric hospital mortality in older adults with COVID-19.

Clinical nutrition (Edinburgh, Scotland)·2021
Same author

Technological readiness and implementation of genomic-driven precision medicine for complex diseases.

Journal of internal medicine·2021
Same author

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2021
Same author

Vascular risk factor control and adherence to secondary preventive medication after ischaemic stroke.

Journal of internal medicine·2020

Fluvoxamine metabolism appears to be influenced by CYP2D6 genetic variations, but not CYP2C19. This finding is crucial for understanding drug disposition in patients with specific cytochrome P450 phenotypes.

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism

Background:

  • Cytochrome P450 enzymes, including CYP2D6 and CYP2C19, play a critical role in drug metabolism.
  • Polymorphisms in these genes can significantly alter drug disposition and efficacy.

Purpose of the Study:

  • To investigate the association between fluvoxamine disposition and CYP2D6/CYP2C19 phenotype polymorphisms.
  • To determine the specific cytochrome P450 enzymes involved in fluvoxamine metabolism.

Main Methods:

  • Administered a single 50 mg oral dose of fluvoxamine to individuals with varying CYP2D6 and CYP2C19 metabolic phenotypes.
  • Monitored serum fluvoxamine concentrations for 48 hours post-administration.
  • Utilized dextromethorphan and mephenytoin as probe drugs to determine CYP2D6 and CYP2C19 phenotypes, respectively.

Related Experiment Videos

Main Results:

  • Individuals with poor CYP2D6 metabolizer phenotype exhibited significantly higher areas under the serum concentration-time curve (AUC) for fluvoxamine compared to extensive metabolizers.
  • No significant differences in fluvoxamine AUC were observed between poor and extensive metabolizers of CYP2C19.

Conclusions:

  • CYP2D6 plays a minor to moderate role in the metabolism of fluvoxamine.
  • CYP2C19 does not appear to significantly influence fluvoxamine disposition.
  • These findings have implications for personalized medicine and optimizing fluvoxamine dosing based on CYP2D6 genotype.